NSE · BALAXI · Pharmaceuticals
Balaxi Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹20 Cr with net profit ₹0 Cr — a 0.79% net margin, versus 6.22% the period before.
Shareholding
As of 2026-06-30
- Promoter65.99%
- Public31.45%
- DII2.56%
14,682 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.42× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #68 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,80,131 Cr | 38.63 | 5.75 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,18,462 Cr | 213.45 | 3.44 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,232 Cr | 20.48 | 4.1 | 18.59% | 18.86% |
| Lupin Limited | ₹1,10,705 Cr | 19.46 | 4.93 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,06,384 Cr | 52.81 | 6.53 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,553 Cr | 432 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹91,552 Cr | 99.39 | 2.42 | 9.25% | 10.5% |
| Alkem Laboratories Ltd. | ₹69,545 Cr | 294.21 | 5.03 | 16.66% | 15.65% |
| Biocon Ltd. | ₹69,034 Cr | 539.11 | 2.03 | 1.14% | 2.3% |
| Balaxi Pharmaceuticals Ltd.(this company) | ₹135 Cr | 222.82 | 0.54 | 0.57% | 0.53% |
AI analysis
AI-generated · google/gemini-2.5-flashBalaxi Pharmaceuticals Ltd. has a market capitalization of Rs 133 Cr. The company reported a revenue of Rs 294.92 Cr and a profit margin of 52.6%. The earnings per share (EPS) stands at 0.26. The 52-week high for the share price was Rs 52.5 and the 52-week low was Rs 15.2. As of March 31, 2026, promoter holding was 65.9906%, with public holding at 31.4487% and DII holding at 2.5607%.
Positives
- +Revenue growth was 21.3% in the latest period.
- +The return on equity (ROE) is 56.9%.
- +Debt-to-equity ratio is low at 0.17.
Negatives
- −The price-to-earnings (PE) ratio is 218.36.
- −The company has a relatively low return on capital employed (ROCE) of 2.9983%.
- −Net profit in the Mar 2026 quarter was Rs 0.61 Cr, lower than the Dec 2024 quarter's net profit of Rs 5.36 Cr.
- −The company is currently under ESM 1 surveillance.
Financial Performance
The company's annual revenue for the latest period was Rs 294.92 Cr, showing a revenue growth of 21.3%. Quarterly revenue for Mar 2026 was Rs 70.71 Cr, with a net profit of Rs 0.61 Cr. The EBITDA for the same quarter was Rs 2.39 Cr. For Dec 2025, revenue was Rs 72.54 Cr and net profit was Rs 0.31 Cr.
Profitability & Returns
Balaxi Pharmaceuticals Ltd. recorded a profit margin of 52.6%. The return on equity (ROE) was 56.9%, while the return on capital employed (ROCE) was 2.9983%. The earnings per share (EPS) for the latest period was 0.26. The price-to-earnings (PE) ratio stands at 218.36.
Balance Sheet
The company's debt-to-equity ratio is 0.17, indicating a relatively low level of debt compared to equity. The book value per share is Rs 45.12. The company does not currently offer a dividend, with a dividend yield of 0%.
Ownership & Pledges
As of March 31, 2026, promoters held 65.9906% of the company's shares. Public shareholding was 31.4487%, and Domestic Institutional Investors (DIIs) held 2.5607%. Foreign Institutional Investors (FIIs) held 0%. There was no promoter share pledge reported.
Regulatory & Surveillance
The company is currently under ESM (Enhanced Surveillance Measure), specifically 'ESM 1', indicating increased scrutiny by regulatory bodies. This measure is in place due to specific criteria met by the company as per regulatory guidelines.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Balaxi Pharmaceuticals Ltd.share price & fundamentals